Formulatrix Announces Licensing Agreement
News Nov 02, 2005
Formulatrix has announced that it has entered into a global licensing agreement with the research division of Novartis for Formulatrix' Rock Maker software.
Rock Maker will integrate Novartis' entire crystallization process including experimental design, liquid handling, imaging, and data management.
Jeremy Stevenson, President of Formulatrix stated, "This deal reinforces our belief that Rock Maker is the premier software solution for automating protein crystallization. This sale also provides us with additional resources to invest into the continued development of Rock Maker."
Formulatrix specializes in providing technology that automates the protein crystallization process, a key part of structure based drug discovery. visit
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE